Dexrazoxane (Zinecard)
Jump to navigation
Jump to search
General information
Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Dexrazoxane (Zinecard) patient drug information (Chemocare)[3]
- Dexrazoxane (Zinecard) patient drug information (UpToDate)[4]